Seroresponse/seroprotection rates for all antigens exceeded prespecified criteria in both groups that received the hexavalent DTaP5-IPV-Hib-HepB ; in the group that received the currently licensed pentavalent vaccine , seroresponse/seroprotection rates exceeded the criteria for all antigens except filamentous hemagglutinin .